EN-US Sat, 25 May 2013 08:33:53 -0400 151317 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AKRUUIMwlvs/shire-drug-to-face-added-competition-analyst-blog-cm151317 Investing Business Stocks Shire ( SHPGY ) recently announced that the US Food and Drug Administration (FDA) has approved the abbreviated new drug application (ANDA) filed by Actavis for its generic version of Adderall<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/AKRUUIMwlvs" height="1" width="1"/> Wed, 27 Jun 2012 01:11:49 Z 2012-06-26T22:14:54Z Zacks Equity Research ANDA IPXL SHPGY TEVA WPI http://www.nasdaq.com/article/shire-drug-to-face-added-competition-analyst-blog-cm151317 143934 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VoSSwd0zglk/shire-presents-data-on-venvanse-analyst-blog-cm143934 Investing Business Stocks Shire ( SHPGY ) recently presented positive results on Venvanse (lisdexamfetamine dimesylate) from a phase III study at the EUNETHYDIS 2nd International Attention-Deficit/Hyperactivity<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/VoSSwd0zglk" height="1" width="1"/> Thu, 24 May 2012 20:43:56 Z 2012-05-24T17:45:59Z Zacks Equity Research JNJ MYL NVS SHPGY WPI http://www.nasdaq.com/article/shire-presents-data-on-venvanse-analyst-blog-cm143934 142054 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/clmEjFrJwJE/watson-and-shire-in-legal-battle-analyst-blog-cm142054 Investing Business Stocks Watson Pharmaceuticals Inc. ( WPI ) recently announced that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for the approval of<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/clmEjFrJwJE" height="1" width="1"/> Thu, 17 May 2012 19:40:40 Z 2012-05-17T16:43:29Z Zacks Equity Research ANDA DEPO SHPGY WPI http://www.nasdaq.com/article/watson-and-shire-in-legal-battle-analyst-blog-cm142054 137230 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dXQa6FlFMK0/revenues-rise-at-shire-analyst-blog-cm137230 Investing Business Stocks Shire plc's ( SHPGY ) first quarter 2012 earnings (excluding special items) of $1.48 per American Depositary Share ( ADS ), were 20% above the year-ago earnings. The year-over-year<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/dXQa6FlFMK0" height="1" width="1"/> Fri, 27 Apr 2012 23:50:23 Z 2012-04-27T20:52:45Z Zacks Equity Research ADS SGMO SHPGY http://www.nasdaq.com/article/revenues-rise-at-shire-analyst-blog-cm137230 135580 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0jsaHcEwiN0/calls-gives-shire-a-bullish-prescription-cm135580 Investing Options As Shire rallied on Friday, traders appeared to have a prescription for more upside. optionMONSTER's Heat Seeker tracking program detected the purchase of 5,000 July 97.50 calls for $6.30<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/0jsaHcEwiN0" height="1" width="1"/> Mon, 23 Apr 2012 13:49:01 Z 2012-04-23T10:49:17Z David Russell SHPGY http://www.nasdaq.com/article/calls-gives-shire-a-bullish-prescription-cm135580 134816 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mgAf-SUCr-U/shire-to-buy-pervasis-therapeutics-analyst-blog-cm134816 Investing Business Stocks Shire plc ( SHPGY ) recently entered into an agreement to acquire almost all the assets of Pervasis Therapeutics. As per the terms of the agreement, Shire will make an upfront payment<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/mgAf-SUCr-U" height="1" width="1"/> Thu, 19 Apr 2012 01:49:24 Z 2012-04-18T22:50:11Z Zacks Equity Research JNJ SGMO SHPGY http://www.nasdaq.com/article/shire-to-buy-pervasis-therapeutics-analyst-blog-cm134816 130985 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-NATT8S3wQg/premarket-most-active-for-mar-30-2012-bac-siri-rimm-dnkn-wmb-qqq-fte-shpgy-vvus-f-nok-bhp-cm130985 News Headlines Investing The NASDAQ 100 Pre-Market Indicator is up 5.1 to 2,767.15. The total Pre-Market volume is currently 5,747,956 shares traded. The following are the most active stocks for the pre-market<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/-NATT8S3wQg" height="1" width="1"/> Fri, 30 Mar 2012 16:39:57 Z 2012-03-30T18:28:37Z NASDAQ.com News BAC BHP DNKN F FTE NOK QQQ RIMM SHPGY SIRI VVUS WMB http://www.nasdaq.com/article/premarket-most-active-for-mar-30-2012-bac-siri-rimm-dnkn-wmb-qqq-fte-shpgy-vvus-f-nok-bhp-cm130985 129228 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h99j5Zm0kZQ/shire-to-buy-ferrokin-biosciences-analyst-blog-cm129228 Investing Business Stocks Shire plc ( SHPGY ) recently entered into an agreement to acquire FerroKin BioSciences, Inc. As per the terms of the agreement, Shire will make an upfront payment of $100 million and<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/h99j5Zm0kZQ" height="1" width="1"/> Fri, 23 Mar 2012 01:22:27 Z 2012-03-22T22:23:56Z Zacks Equity Research JNJ SGMO SHPGY http://www.nasdaq.com/article/shire-to-buy-ferrokin-biosciences-analyst-blog-cm129228 129221 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TH0O35Bz6ZA/replagal-bla-withdrawn-by-shire-analyst-blog-cm129221 Investing Business Stocks Shire plc ( SHPGY ) recently announced that it has withdrawn its US marketing application for Replagal. Shire had submitted the Biologics License Application (BLA) for Replagal with<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/TH0O35Bz6ZA" height="1" width="1"/> Fri, 23 Mar 2012 00:15:01 Z 2012-03-22T21:24:08Z Zacks Equity Research SHPGY SNY http://www.nasdaq.com/article/replagal-bla-withdrawn-by-shire-analyst-blog-cm129221 127058 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mCSrzfHK3M4/shires-fosrenol-oral-powder-approved-analyst-blog-cm127058 Investing Business Stocks Shire ( SHPGY ) announced that it has received approval for its oral powder formulation of Fosrenol (lanthanum carbonate), a phosphate binding agent, through the European Decentralised<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/mCSrzfHK3M4" height="1" width="1"/> Wed, 14 Mar 2012 01:11:01 Z 2012-03-13T22:23:23Z Zacks Equity Research MYL SHPGY http://www.nasdaq.com/article/shires-fosrenol-oral-powder-approved-analyst-blog-cm127058 126464 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/F2xJ93qm-7g/shire-initiates-trials-for-vyvanse-analyst-blog-cm126464 Investing Business Stocks Recently, Shire ( SHPGY ) announced the initiation of two phase IV trials of Vyvanse (lisdexamfetamine dimesylate) capsules. Vyvanse is currently marketed for attention-deficit<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/F2xJ93qm-7g" height="1" width="1"/> Sat, 10 Mar 2012 03:20:01 Z 2012-03-10T01:22:01Z Zacks Equity Research JNJ MYL NVS SHPGY WPI http://www.nasdaq.com/article/shire-initiates-trials-for-vyvanse-analyst-blog-cm126464 125026 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_cFnHmEQI8o/sny-starts-delivering-from-new-unit-analyst-blog-cm125026 Investing Business Stocks Sanofi's ( SNY ) subsidiary, Genzyme, announced that it has begun shipping Fabrazyme (agalsidase beta) from its recently approved Framingham manufacturing facility. The Framingham unit<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/_cFnHmEQI8o" height="1" width="1"/> Mon, 05 Mar 2012 20:45:01 Z 2012-03-05T18:05:57Z Zacks Equity Research SHPGY SNY http://www.nasdaq.com/article/sny-starts-delivering-from-new-unit-analyst-blog-cm125026 124736 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PDX6wxQZcmk/shire-and-argenx-ink-deal-analyst-blog-cm124736 Investing Business Stocks Shire ( SHPGY ) recently entered into an agreement with arGEN-X, a Netherlands-based privately-held biopharmaceutical company, to create novel treatments for rare genetic diseases.<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/PDX6wxQZcmk" height="1" width="1"/> Sat, 03 Mar 2012 02:05:01 Z 2012-03-02T23:01:44Z Zacks Equity Research IPXL MYL SHPGY TEVA WPI http://www.nasdaq.com/article/shire-and-argenx-ink-deal-analyst-blog-cm124736 123428 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lTGPNPgAcUw/ema-approves-shires-vpriv-unit-analyst-blog-cm123428 Investing Business Stocks Recently, Shire plc ( SHPGY ) announced that it has received approval for a manufacturing facility of Vpriv from the European Medicines Agency's ("EMA") Committee for<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/lTGPNPgAcUw" height="1" width="1"/> Tue, 28 Feb 2012 04:44:01 Z 2012-02-28T01:06:50Z Zacks Equity Research SHPGY SNY http://www.nasdaq.com/article/ema-approves-shires-vpriv-unit-analyst-blog-cm123428 120327 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9m_DSmhAaco/shire-beats-estimates-all-the-way-analyst-blog-cm120327 Investing Business Stocks Shire plc's ( SHPGY ) fourth quarter 2011 earnings (excluding special items) of $1.51 per American Depository Share ("ADS"), were 47% above the year-ago earnings. The<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/9m_DSmhAaco" height="1" width="1"/> Mon, 13 Feb 2012 19:30:01 Z 2012-02-13T17:10:08Z Zacks Equity Research SHPGY http://www.nasdaq.com/article/shire-beats-estimates-all-the-way-analyst-blog-cm120327